Genetic heterogeneity of the envelope 2 gene and eradication of hepatitis C virus after a second course of interferon‐α
暂无分享,去创建一个
C. Pasquier | J. Puel | J. Izopet | J. Vinel | L. Alric | M. Dubois | J. Payen | J. Pascal | A. Boulestin | K. Sandres-Sauné
[1] A. Alberti,et al. Two PKR inhibitor HCV proteins correlate with early but not sustained response to interferon. , 2000, Gastroenterology.
[2] M. Shaw,et al. The Amino Acid Sequence of the PKR-eIF2α Phosphorylation Homology Domain of Hepatitis C Virus Envelope 2 Protein and Response to Interferon-α , 2000 .
[3] S. Polyak,et al. The protein kinase-interacting domain in the hepatitis C virus envelope glycoprotein-2 gene is highly conserved in genotype 1-infected patients treated with interferon. , 2000, The Journal of infectious diseases.
[4] B. Kronenberger,et al. Mutations within the E2 and NS5A protein in patients infected with hepatitis C virus type 3a and correlation with treatment response , 2000 .
[5] B. Walker,et al. Analysis of Successful Immune Responses in Persons Infected with Hepatitis C Virus , 2000, The Journal of experimental medicine.
[6] H J Alter,et al. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. , 2000, Science.
[7] O. Laeyendecker,et al. Hypervariable Region 1 Sequence Stability during Hepatitis C Virus Replication in Chimpanzees , 2000, Journal of Virology.
[8] C. Pasquier,et al. Genetic Heterogeneity of Hypervariable Region 1 of the Hepatitis C Virus (HCV) Genome and Sensitivity of HCV to Alpha Interferon Therapy , 2000, Journal of Virology.
[9] R. Purcell,et al. Quasispecies in viral persistence and pathogenesis of hepatitis C virus. , 1999, Trends in microbiology.
[10] D. R. Taylor,et al. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. , 1999, Science.
[11] J Cohen,et al. The Scientific Challenge of Hepatitis C , 1999, Science.
[12] J. Berzofsky,et al. T cell recognition of hypervariable region-1 from hepatitis C virus envelope protein with multiple class II MHC molecules in mice and humans: preferential help for induction of antibodies to the hypervariable region. , 1999, Journal of immunology.
[13] J. Puel,et al. Better efficacy of a 12‐month interferon alfa‐2b retreatment in patients with chronic hepatitis C relapsing after a 6‐month treatment: A multicenter, controlled, randomized trial , 1998, Hepatology.
[14] J. Hoefs,et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.
[15] William M. Lee,et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. , 1998, The New England journal of medicine.
[16] P. Marcellin,et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus , 1998, The Lancet.
[17] Oliver Laeyendecker,et al. Assessment of Hepatitis C Virus Sequence Complexity by Electrophoretic Mobilities of Both Single-and Double-Stranded DNAs , 1998, Journal of Clinical Microbiology.
[18] M. von Wagner,et al. Effect of ribavirin on virus load and quasispecies distribution in patients infected with hepatitis C virus. , 1998, Journal of hepatology.
[19] J. Pawlotsky,et al. Genetic complexity of the hypervariable region 1 (HVR1) of hepatitis C virus (HCV): Influence on the characteristics of the infection and responses to interferon alfa therapy in patients with chronic hepatitis C , 1998, Journal of medical virology.
[20] J. Puel,et al. Baseline level and early suppression of serum HCV RNA for predicting sustained complete response to alpha‐interferon therapy , 1998, Journal of medical virology.
[21] C. Bréchot,et al. Hepatitis C virus genome complexity correlates with response to interferon therapy: A study in French patients with chronic hepatitis C , 1997, Hepatology.
[22] L. Corey,et al. Assessment of hepatitis C virus quasispecies heterogeneity by gel shift analysis: correlation with response to interferon therapy. , 1997, The Journal of infectious diseases.
[23] J. Hoofnagle,et al. THE TREATMENT OF CHRONIC VIRAL HEPATITIS , 1997 .
[24] G. Davis,et al. Clinical implications of viral quasispecies heterogeneity in chronic hepatitis C , 1996, Journal of medical virology.
[25] N. Enomoto,et al. Diversity of quasispecies in various disease stages of chronic hepatitis C virus infection and its significance in interferon treatment , 1995, Hepatology.
[26] H. Fusamoto,et al. Hepatitis C viral complexity detected by single-strand conformation polymorphism and response to interferon therapy. , 1995, Gastroenterology.
[27] J. Thompson,et al. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.
[28] M. Honda,et al. Degree of diversity of hepatitis C virus quasispecies and progression of liver disease , 1994, Hepatology.
[29] N. Hayashi,et al. Influence of viral quasispecies on effectiveness of interferon therapy in chronic hepatitis C patients , 1994, Hepatology.
[30] R. Purcell,et al. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses , 1994, Journal of virology.
[31] N. Kato,et al. Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus , 1993, Journal of virology.
[32] S. Mishiro,et al. The degree of variability in the amino terminal region of the E2/NS1 protein of hepatitis C virus correlates with responsiveness to interferon therapy in viremic patients , 1992, Hepatology.
[33] A. Weiner,et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution , 1992, Journal of virology.
[34] Giorgio,et al. Evidence for immune selection of hepatitis C virus (HCV) putative envelope glycoprotein variants: potential role in chronic HCV infections. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[35] R. Purcell,et al. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[36] R. Purcell,et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. , 1989, The New England journal of medicine.
[37] Miguel Ángel Martínez,et al. Implications of a quasispecies genome structure: effect of frequent, naturally occurring amino acid substitutions on the antigenicity of foot-and-mouth disease virus. , 1989, Proceedings of the National Academy of Sciences of the United States of America.